OncoSil Medical Future Growth

Future criteria checks 0/6

We currently don't have sufficient analyst coverage to forecast growth and revenue for OncoSil Medical.

Key information

n/a

Earnings growth rate

n/a

EPS growth rate

Life Sciences earnings growth	20.3%
Revenue growth rate	n/a
Future return on equity	n/a
Analyst coverage	None
Last updated	n/a

Recent future growth updates

Recent updates

How Much Did OncoSil Medical's(ASX:OSL) Shareholders Earn From Share Price Movements Over The Last Year?

Dec 04

In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as OncoSil Medical has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.

This is quite a rare situation as 97% of companies covered by SimplyWall St do have past financial data.

Earnings and Revenue Growth Forecasts

ASX:OSL - Analysts future estimates and past financials data (AUD Millions)
Date	Revenue	Earnings	Free Cash Flow	Cash from Op	Avg. No. Analysts
6/30/2024	2	-12	-11	-11	N/A
3/31/2024	1	-12	-11	-11	N/A
12/31/2023	1	-12	-10	-10	N/A
9/30/2023	1	-12	-11	-11	N/A
6/30/2023	1	-11	-11	-11	N/A
3/31/2023	1	-11	-11	-11	N/A
12/31/2022	1	-11	-10	-10	N/A
9/30/2022	1	-11	-10	-10	N/A
6/30/2022	1	-11	-10	-10	N/A
3/31/2022	1	-11	-11	-11	N/A
12/31/2021	1	-11	-11	-11	N/A
9/30/2021	1	-11	-10	-10	N/A
6/30/2021	1	-10	-9	-9	N/A
3/31/2021	2	-8	-8	-8	N/A
12/31/2020	2	-6	-7	-7	N/A
9/30/2020	2	-5	-6	-6	N/A
6/30/2020	3	-4	-4	-4	N/A
3/31/2020	3	-6	-5	-5	N/A
12/31/2019	3	-7	-6	-6	N/A
9/30/2019	3	-8	-7	-7	N/A
6/30/2019	4	-9	-8	-8	N/A
3/31/2019	4	-9	-8	-8	N/A
12/31/2018	4	-9	-8	-8	N/A
9/30/2018	4	-9	-8	-8	N/A
6/30/2018	4	-9	-8	-8	N/A
3/31/2018	4	-8	N/A	-8	N/A
12/31/2017	4	-8	N/A	-7	N/A
9/30/2017	4	-8	N/A	-7	N/A
6/30/2017	4	-7	N/A	-6	N/A
3/31/2017	3	-7	N/A	-6	N/A
12/31/2016	2	-6	N/A	-5	N/A
9/30/2016	3	-5	N/A	-5	N/A
6/30/2016	4	-5	N/A	-5	N/A
3/31/2016	4	-3	N/A	-3	N/A
12/31/2015	4	-2	N/A	-1	N/A
9/30/2015	3	-3	N/A	0	N/A
6/30/2015	3	-3	N/A	0	N/A
3/31/2015	2	-5	N/A	N/A	N/A
12/31/2014	2	-7	N/A	-5	N/A
9/30/2014	1	-7	N/A	-6	N/A
6/30/2014	0	-7	N/A	-6	N/A
3/31/2014	0	-5	N/A	N/A	N/A

Analyst Future Growth Forecasts

Earnings vs Savings Rate: Insufficient data to determine if OSL's forecast earnings growth is above the savings rate (2.6%).

Earnings vs Market: Insufficient data to determine if OSL's earnings are forecast to grow faster than the Australian market

High Growth Earnings: Insufficient data to determine if OSL's earnings are expected to grow significantly over the next 3 years.

Revenue vs Market: Insufficient data to determine if OSL's revenue is forecast to grow faster than the Australian market.

High Growth Revenue: Insufficient data to determine if OSL's revenue is forecast to grow faster than 20% per year.

Earnings per Share Growth Forecasts

Future Return on Equity

Future ROE: Insufficient data to determine if OSL's Return on Equity is forecast to be high in 3 years time

Discover growth companies

Company Analysis and Financial Data Status

Data	Last Updated (UTC time)
Company Analysis	2024/12/31 06:57
End of Day Share Price	2024/12/31 00:00
Earnings	2024/06/30
Annual Earnings	2024/06/30

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

Package	Data	Timeframe	Example US Source ^*
Company Financials	10 years	Income statement Cash flow statement Balance sheet	SEC Form 10-K SEC Form 10-Q
Analyst Consensus Estimates	+3 years	Forecast financials Analyst price targets	Analyst Research Reports Blue Matrix
Market Prices	30 years	Stock prices Dividends, Splits and Actions	ICE Market Data SEC Form S-1
Ownership	10 years	Top shareholders Insider trading	SEC Form 4 SEC Form 13D
Management	10 years	Leadership team Board of directors	SEC Form 10-K SEC Form DEF 14A
Key Developments	10 years	Company announcements	SEC Form 8-K

^* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

OncoSil Medical Limited is covered by 3 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

Analyst	Institution
John Hester	Bell Potter
Thomas Duthy	Taylor Collison Limited
Shane Storey	Wilsons Advisory and Stockbroking Ltd.

OncoSil Medical Future Growth

Future criteria checks 0/6

Key information

Recent future growth updates

Forecast to breakeven in 2025

Forecast to breakeven in 2025

Price target increased to AU$0.17

Analysts lower revenue estimates to AU$189.0k

Price target lowered to AU$0.34

Analysts update estimates

Recent updates

OncoSil Medical Limited has filed a Follow-on Equity Offering in the amount of AUD 1 million.

OncoSil Medical Limited, Annual General Meeting, Nov 20, 2024

Full year 2024 earnings released: AU$0.005 loss per share (vs AU$0.01 loss in FY 2023)

Peter Hall Elects Not to Join Oncosil Medical Limited's Board

Full year 2024 earnings released: AU$0.006 loss per share (vs AU$0.01 loss in FY 2023)

OncoSil Medical Limited Appoints Peter Hall as Non-Executive Director

OncoSil Medical Limited has filed a Follow-on Equity Offering in the amount of AUD 2.7 million.

New major risk - Market cap size

OncoSil Medical Limited has filed a Follow-on Equity Offering in the amount of AUD 1.48 million.

New major risk - Market cap size

Oncosil Medical Limited Elects Gabrielle Liberatore as Director

New major risk - Market cap size

New major risk - Share price stability

OncoSil Medical Limited, Annual General Meeting, Nov 29, 2023

Full year 2023 earnings released: AU$0.01 loss per share (vs AU$0.013 loss in FY 2022)

OncoSil Appoints Gabriel Liberatore to the Board

OncoSil Medical Limited Announces Appointment of Dal Cin as Chief Financial Officer

Oncosil Medical Ltd Announces Resignation of Karl Pechmann as Chief Financial Officer

Insider recently bought AU$1.2m worth of stock

First half 2023 earnings released: AU$0.006 loss per share (vs AU$0.007 loss in 1H 2022)

Oncosil Medical Limited Announces Two Key Treatment Centres Treat First Patients with Oncosil

OncoSil Medical Limited has completed a Follow-on Equity Offering in the amount of AUD 6.09495 million.

Forecast to breakeven in 2025

Less than half of directors are independent

OncoSil Medical Limited Announces Resignation of Martin Cross as Director

OncoSil Medical Ltd Appoints Brian Leedman to the Board as a Non-Executive Director

Forecast to breakeven in 2025

Full year 2022 earnings: Revenues exceed analysts expectations while EPS lags behind

OncoSil Medical Limited, Annual General Meeting, Oct 25, 2022

Oncosil Medical Ltd Announces Second Patient Treated in Spain Proceeds to Successful Resection

Companies Like OncoSil Medical (ASX:OSL) Could Be Quite Risky

Less than half of directors are independent

OncoSil Medical Ltd. Announces the First Commercial Treatment of the OncoSilTM Device in Europe

OncoSil Medical Limited Announces Fully-Funded Trial Approval in Germany To Increase Sales of OncoSil Device

Price target increased to AU$0.17

First half 2022 earnings: Revenues exceed analysts expectations while EPS lags behind

Here's Why We're Watching OncoSil Medical's (ASX:OSL) Cash Burn Situation

Oncosil Medical Limited announces PanCO Clinical Study on OncoSil(TM) Published in ESMO Open

Less than half of directors are independent

Is OncoSil Medical (ASX:OSL) In A Good Position To Deliver On Growth Plans?

Full year 2021 earnings released: AU$0.013 loss per share (vs AU$0.006 loss in FY 2020)

OncoSil Medical Limited Provides Update on TGA Regulatory

OncoSil Medical (ASX:OSL) Is In A Good Position To Deliver On Growth Plans

OncoSil Medical's (ASX:OSL) Stock Price Has Reduced 42% In The Past Five Years

Analysts lower revenue estimates to AU$189.0k

Price target lowered to AU$0.34

First half 2021 earnings released: AU$0.006 loss per share (vs AU$0.005 loss in 1H 2020)

OncoSil Medical Limited Announces Executive Appointments

We're Not Worried About OncoSil Medical's (ASX:OSL) Cash Burn

OncoSil Medical Limited Appoints Nigel Lange as Chief Executive Officer

How Much Did OncoSil Medical's(ASX:OSL) Shareholders Earn From Share Price Movements Over The Last Year?

OncoSil Medical Limited Announces Executive Changes

OncoSil Medical Limited Receives Swiss Regulatory Approval

Independent Non-Executive Chairman recently bought AU$405k worth of stock

Analysts update estimates

Earnings and Revenue Growth Forecasts

Analyst Future Growth Forecasts

Earnings per Share Growth Forecasts

Future Return on Equity

Discover growth companies

Company Analysis and Financial Data Status

Data Sources

Analysis Model and Snowflake

Industry and Sector Metrics

Analyst Sources